Oslo, January 10,
The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor pledged to dispose of all its non-HIV activities. These activities have now been transferred to Immunor through a mutual assignment agreement where Immunor acquires all of Bionor’s non-HIV activities in exchange for CRX. Immunor AS has been working on the development of CRX since 2014.
CRX aims to prevent binding between gp 120 V3 loop and CCR5/CXCR4 co-receptors and is expected to carry neutralizing properties. This 3rd principle in Bionor´s HIV project portfolio will therefore in combination with Bionor’s Vacc-4x and Vacc-C5 constitute a strong addition to Bionor’s Functional HIV Cure strategy.